Clinical trial · Observational
Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer
A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer
NCT02161315CI-TRIAL-00020292unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Steroid Aromatase Inhibitors and Non-Steroid Aromatase Inhibitors in Late Stage Breast Cancer is the recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. In the past controlled clinical trials with small sample.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma Breast Stage IV | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Observation group
- description
- Steroid Aromatase Inhibitors
- label
- Control group
- description
- Non-Steroid Aromatase Inhibitor
Primary outcomes (1)
- measure
- RECIST 1.1
- timeFrame
- -7 days
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: 1. Patients must be the postmenopausal women 2. Patients must be diagnosed with advanced breast cancer by imageology，cytology or histopathology 3. Immunohistochemistry shows ER and/or PR positive 4. Patients ECOG score must be 0-2 5. Drug resistant about Non-Steroid Aromatase Inhibitors Exclusion Criteria: 1. Not suitable for endocrine therapy 2. Have receive the standard Steroid Aromatase Inhibitors treatment 3. Severe hepatic dysfunction
References
Publications (0)
Data not yet available
No reference posted for this study.